strontium ranelate
Trade name: Protelos
Strontium ranelate, a strontium(II) salt of ranelic acid, is a medication for osteoporosis marketed as Protelos or Protos by Servier. Studies indicate it can also slow the course of osteoarthritis of the knee. The drug is unusual in that it both increases deposition of new bone by osteoblasts and reduces the resorption of bone by osteoclasts. It is therefore promoted as a "dual action bone agent" (DABA). — Wikipedia
Clinical trial activity
6 trials · 7 clinical orgs · 0 marketing orgs
Earliest trial started Sep 1, 2005 (NCT00239629)
Timeline
No events for the selected filters.
Indications
Approved for
Mechanism of action
- OsteoclastINHIBITOR
Osteoclast inhibitor
Possibly activates the calcium sensing receptor; https://www.mdpi.com/2218-273X/11/11/1576.
- Unspecified targetOTHER
Unknown
Possibly activates the calcium sensing receptor; https://www.mdpi.com/2218-273X/11/11/1576.
Chemistry & pharmacology
SMILES
N#Cc1c(N(CC(=O)[O-])CC(=O)[O-])sc(C(=O)[O-])c1CC(=O)[O-].[Sr+2].[Sr+2]- Mol. weight
- 513.49 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaStrontium ranelate ↗
- ChEMBLCHEMBL3707306 ↗
Also known as
- 3-(3-cyano-4-carboxymethyl-5-carboxy-2-thienyl)-3-azapentanedioic distrontium salt
- bivalos
- distrontium renelate
- osseor
- protelos
- protelos
- protelos
- protelos
- s12911
- s 12911
- s-12911
- s12911-0
- s12911-2
- s12911-5
- strontium ranelate
- strontium ranelate
- strontium ranelate
- strontium ranelate
- strontium ranelate
- strontium ranelate
- strontium ranelate
- strontium ranelate
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05712616 | Phase 4 | Nov 1, 2021 | Aga Khan University |
| NCT03937518 | N/A | Jan 1, 2017 | Mansoura University |
| NCT01222026 | Phase 4 | Sep 1, 2010 | National Bank of Austria, University of Vienna |
| NCT01544894 | Phase 4 | Sep 1, 2009 | University of Valencia |
| NCT00479037 | Phase 4 | Apr 1, 2007 | Nycomed |
| NCT00239629 | Phase 4 | Sep 1, 2005 | Eli Lilly |
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aga Khan University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Eli Lilly | For profit | 1 | 1 | 1 | 2005 |
| Mansoura University | Academic/Hospital | 1 | 1 | 1 | 2017 |
| National Bank of Austria | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Nycomed | For profit | 1 | 1 | 1 | 2007 |
| University of Valencia | Academic/Hospital | 1 | 1 | 1 | 2009 |
| University of Vienna | Academic/Hospital | 1 | 1 | 1 | 2010 |